U.S. Markets closed

Johnson & Johnson Unveils 5-Year Growth Plan for Pharmaceutical Business

M. Corey Goldman

on Wednesday revealed its plans to boost growth within its Janssen pharmaceutical business over the next five years, including seeking regulatory approval for more than 40 line-extensions of its therapies and treatments currently in development. At a meeting on Wednesday with industry analysts to review its Janssen pharmaceutical business and discuss its progress and pipeline developments, the company said it is exploring additional regulatory approvals for multiple drugs it is currently working on. Additional medicines will be discussed that have the potential to file or launch by 2023, including four that are new to Johnson & Johnson's pipeline, as well as gene therapy and RNA therapeutics treatments that are in more advanced stages of development, the company said.